Author

Philippe Gual

INSERM U1065, C3M, Universit

Biography

Philippe Gual is currently working in The Complications Complications hépatiquesUniversitaire ARCHIMED Nice, France. Philippe Gual international experience includes various programs, contributions and participation in different countries for diverse fields of study. Philippe Gual research interests reflect wide range of publications in various national and international journals.
Title
Cited by
Year
Guidelines for the use and interpretation of assays for monitoring autophagy (4th edition)1
DJ Klionsky, AK Abdel-Aziz, S Abdelfatah, M Abdellatif, A Abdoli, S Abel, ...autophagy 17 (1), 1-382, 202112193202
12193
2021
Compounds triggering ER stress exert anti-melanoma effects and overcome BRAF inhibitor resistance
M Cerezo, A Lehraiki, A Millet, F Rouaud, M Plaisant, E Jaune, T Botton, ...Cancer cell 29 (6), 805-819, 2016201
210
2016
Metabolism dysregulation induces a specific lipid signature of nonalcoholic steatohepatitis in patients
F Chiappini, A Coilly, H Kadar, P Gual, A Tran, C Desterke, D Samuel, ...Scientific reports 7 (1), 46658, 2017201
164
2017
Visceral adipose tissue drives cardiac aging through modulation of fibroblast senescence by osteopontin production
D Sawaki, G Czibik, M Pini, J Ternacle, N Suffee, R Mercedes, G Marcelin, ...Circulation 138 (8), 809-822, 2018201
115
2018
CD44 is a key player in non-alcoholic steatohepatitis
S Patouraux, D Rousseau, S Bonnafous, C Lebeaupin, C Luci, ...Journal of hepatology 67 (2), 328-338, 2017201
99
2017
Chronic inflammation in non-alcoholic steatohepatitis: molecular mechanisms and therapeutic strategies
C Luci, M Bourinet, PS Leclère, R Anty, P GualFrontiers in endocrinology 11, 597648, 2020202
90
2020
Bax inhibitor‐1 protects from nonalcoholic steatohepatitis by limiting inositol‐requiring enzyme 1 alpha signaling in mice
C Lebeaupin, D Vallée, D Rousseau, S Patouraux, S Bonnafous, G Adam, ...Hepatology 68 (2), 515-532, 2018201
82
2018
Autophagy in chronic liver diseases: the two faces of Janus
P Gual, H Gilgenkrantz, S LotersztajnAmerican Journal of Physiology-Cell Physiology 312 (3), C263-C273, 2017201
72
2017
Natural killer cells and type 1 innate lymphoid cells are new actors in non-alcoholic fatty liver disease
C Luci, E Vieira, T Perchet, P Gual, R GolubFrontiers in Immunology 10, 1192, 2019201
67
2019
Screening for therapeutic trials and treatment indication in clinical practice: MACK‐3, a new blood test for the diagnosis of fibrotic NASH
J Boursier, R Anty, L Vonghia, V Moal, T Vanwolleghem, CM Canivet, ...Alimentary pharmacology & therapeutics 47 (10), 1387-1396, 2018201
63
2018
Roux-en Y gastric bypass results in long-term remission of hepatocyte apoptosis and hepatic histological features of non-alcoholic steatohepatitis
AS Schneck, R Anty, S Patouraux, S Bonnafous, D Rousseau, ...Frontiers in Physiology 7, 344, 2016201
36
2016
Early postnatal soluble FGFR3 therapy prevents the atypical development of obesity in achondroplasia
C Saint-Laurent, S Garcia, V Sarrazy, K Dumas, F Authier, S Sore, A Tran, ...PLoS One 13 (4), e0195876, 2018201
34
2018
Severe vitamin D deficiency is not associated with liver damage in morbidly obese patients
R Anty, A Hastier, CM Canivet, S Patouraux, AS Schneck, ...Obesity surgery 26, 2138-2143, 2016201
28
2016
Hepatic FNDC5 is a potential local protective factor against Non-Alcoholic Fatty Liver
CM Canivet, S Bonnafous, D Rousseau, PS Leclere, S Lacas-Gervais, ...Biochimica et Biophysica Acta (BBA)-Molecular Basis of Disease 1866 (5), 165705, 2020202
28
2020
Baseline anthropometric and metabolic parameters correlate with weight loss in women 1-year after laparoscopic Roux-En-Y gastric bypass
A Sans, L Bailly, R Anty, I Sielezenef, J Gugenheim, A Tran, P Gual, ...Obesity surgery 27, 2940-2949, 2017201
25
2017
The differential expression of cide family members is associated with nafld progression from steatosis to steatohepatitis
A Sans, S Bonnafous, D Rousseau, S Patouraux, CM Canivet, PS Leclere, ...Scientific reports 9 (1), 7501, 2019201
25
2019
Pathogenesis of non-alcoholic fatty liver disease
R Anty, P GualPresse Medicale (Paris, France: 1983) 48 (12), 1468-1483, 2019201
22
2019
Metabolic fatty liver disease in children: A growing public health problem
S Le Garf, V Nègre, R Anty, P GualBiomedicines 9 (12), 15, 2021202
19
2021
Non-invasive evaluation of NAFLD with indocyanine green clearance test: a preliminary study in morbidly obese patients undergoing bariatric surgery
PE Danin, R Anty, S Patouraux, M Raucoules-Aimé, J Gugenheim, A Tran, ...Obesity Surgery 28, 735-742, 202
18
2018
Therapeutic potential of nicotinamide adenine dinucleotide for nonalcoholic fatty liver disease
P Gual, C PosticHepatology 63 (4), 1074-1077, 2016201
18
2016

Referred From: https://scholar.google.com/citations?user=IRxg4lsAAAAJ&hl=fr

Cited by
Citations 22240
h-index 50
i10-index 85
Recommended Journals
Open Access Journals